| 1.39 0 (0%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.31 | 1-year : | 2.81 |
| Resists | First : | 1.98 | Second : | 2.41 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.37 | MA(20) : | 1.59 |
| MA(100) : | 2.13 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 11.5 |
| RSI | RSI(14): 31.2 | |||
| 52-week | High : | 3.61 | Low : | 0.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIAF ] has closed above bottom band by 24.6%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.45 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.37 - 1.39 | 1.39 - 1.4 |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Fri, 23 Aug 2024
bioAffinity Technologies Announces CFO Transition and Appointment - TipRanks
Fri, 23 Aug 2024
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO - Business Wire
Fri, 12 Jul 2024
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Tue, 09 Jul 2024
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 8.66e+006 (%) |
| Held by Institutions | 32.5 (%) |
| Shares Short | 604 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.03e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -119.5 % |
| Operating Margin | -87.1 % |
| Return on Assets (ttm) | -69.8 % |
| Return on Equity (ttm) | -151.6 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 291910 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|